Executive record

Kevin Tang

Director at Aurinia Pharmaceuticals Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:kevin-tangVersion: public-0As of: 2026-09-29

Not yet claimed9 published Claims3 sources
  • Director

Key Claims

Biography

Kevin Tang is President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. He has extensive experience forming and building biotechnology companies, including serving as Chairman of La Jolla Pharmaceutical Company and founding Odonate Therapeutics, Inc. and Heron Therapeutics, Inc.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. Dates not publishedExecutive title: Chief Executive Officer and Chair of the Board · Organization not publishedAUPH DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. AUPH DEF 14A director slate

    sec filing · Source published: Apr 21, 2026 · Retrieved: May 15, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Chair · Claim reviewed: May 15, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Executive company: Executive at Aurinia Pharmaceuticals Inc. · Claim reviewed: May 15, 2026
    • Executive title: Executive title: Chief Executive Officer and Chair of the Board · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 21, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Aurinia Pharmaceuticals Inc. · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Aurinia Pharmaceuticals Inc. · Claim reviewed: May 15, 2026